Andy i. m. Hoepelman - Infectious Diseases

Author Information

Andy I. M. Hoepelman is a prominent researcher affiliated with the University Medical Centre Utrecht, specifically within the Department of Internal Medicine and Infectious Diseases in Utrecht, Netherlands. His work has significantly contributed to the field of infectious diseases, with a particular focus on HIV and hepatitis co-infections. The affiliation details are sourced from PubMed.

Research Contributions

Andy I. M. Hoepelman has made substantial contributions to the study of infectious diseases, as evidenced by his extensive publication record. His research encompasses a wide range of topics including the epidemiology and treatment of chronic hepatitis C, the implications of antiretroviral therapy in HIV patients, and the impact of viral co-infections on health outcomes. Notable studies include the assessment of mortality outcomes with hydroxychloroquine and chloroquine in COVID-19, and the investigation into the incidence of HIV-1 blips during integrase inhibitor-based therapies. His work often involves collaborative and multi-disciplinary approaches to address complex health issues.

Aliases

Throughout his career, Andy I. M. Hoepelman has been referenced under various aliases including A I Hoepelman, Andy I.m. Hoepelman, and A. I. M. Hoepelman, among others. These variations are common in academic publications and databases, reflecting different formats and initials used in his publications.

Publication and Citation Metrics

Metric	Value
Total Papers Published	224
Total Citation Count	9238
H-index	47

Publications:

Estimating regional prevalence of chronic hepatitis C with a capture-recapture analysis

DOI: 10.1186/s12879-021-06324-z

Year: 2021

Dual Antiretroviral Therapy—All Quiet Beneath the Surface?

DOI: 10.3389/fimmu.2021.637910

Year: 2021

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

DOI: 10.1038/s41467-021-22446-z

Year: 2021

Lower incidence of HIV-1 blips observed during integrase inhibitor-based combination antiretroviral therapy.

DOI: 10.1097/QAI.0000000000002898

Year: 2021

Decreased All-Cause and Liver-Related Mortality Risk in HIV/Hepatitis B Virus Coinfection Coinciding With the Introduction of Tenofovir-Containing Combination Antiretroviral Therapy

DOI: 10.1093/ofid/ofaa226

Year: 2020

Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency.

DOI: 10.1182/blood.2020006738

Year: 2020

High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients

DOI: 10.1007/s13365-020-00860-1

Year: 2020

The balancing perspective of hard-to-reach hepatitis C patients who were lost to follow-up: A qualitative study

DOI: 10.1371/journal.pone.0230756

Year: 2020

A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?

DOI: 10.1007/s40121-018-0229-7

Year: 2019

Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy

DOI: 10.1016/j.eclinm.2019.11.003

Year: 2019

What is Dexamethasone?

What Diseases Require Quarantine?

What Ongoing Research is Being Conducted?

How Do Masks Work?

How Does Lipid Metabolism Influence Pathogen Resistance?

Are There Metabolic Pathway Differences Between Pathogens and Hosts?

How Does the NIH Support Global Health?

How are Infectious Diseases Treated?

What is the correct way to wash your hands?

How Are STIs Diagnosed?

Partnered Content Networks

Relevant Topics